Related Experiment Video
Updated: Aug 22, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
The potential of PDE4 inhibitors in respiratory disease
1The Sackler Institute of Pulmonary Pharmacology, Hodgkin Building, GKT School of Biomedical Science, Kings College London, SE1 1UL, UK. domenico.spina@kcl.ac.uk
Abstract:
Glucocorticosteroids remain the gold standard therapy for the prophylactic treatment of asthma. Concerns regarding its long-term use particularly in young children has provided an impetus for discovering novel anti-inflammatory molecules with high tolerability and clinical efficacy. Whilst for chronic obstructive pulmonary disease (COPD), there exist no pharmacological treatment for the prevention of decline in lung function. Targeting phosphodiesterase (PDE)4 is one example of this approach and inhibitors of this enzyme are the most advanced drug class in the respiratory pipeline. A number of potent PDE4 inhibitors have undergone clinical trials with moderate success. Tolerability and clinical efficacy issues have dampened enthusiasm in this area. However, with the prospect of newer potent and side effect free inhibitors on the horizon give this area guarded optimism. This review will summarise the most recent information concerning the effectiveness of PDE4 inhibitors as novel anti-inflammatory agents for the treatment of respiratory diseases.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
